Log in
NYSE:CTLT

Catalent Stock Forecast, Price & News

$97.40
+2.75 (+2.91 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$94.75
Now: $97.40
$97.45
50-Day Range
$87.77
MA: $96.70
$105.36
52-Week Range
$31.04
Now: $97.40
$120.48
Volume686,452 shs
Average Volume1.36 million shs
Market Capitalization$16.04 billion
P/E Ratio62.04
Dividend YieldN/A
Beta1.59
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
Catalent logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200
Employees13,900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 billion
Cash Flow$3.86 per share
Book Value$18.65 per share

Profitability

Net Income$173 million

Miscellaneous

Market Cap$16.04 billion
Next Earnings Date2/1/2021 (Estimated)
OptionableOptionable
$97.40
+2.75 (+2.91 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalent (NYSE:CTLT) Frequently Asked Questions

How has Catalent's stock been impacted by COVID-19?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTLT stock has increased by 111.5% and is now trading at $97.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catalent?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalent
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalent wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Monday, February 1st 2021.
View our earnings forecast for Catalent
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.37 by $0.06. The business had revenue of $845.70 million for the quarter, compared to analysts' expectations of $812.87 million. Catalent had a return on equity of 14.20% and a net margin of 9.25%. The company's revenue was up 27.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS.
View Catalent's earnings history
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2021 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share guidance of 2.30-2.61 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $3.58-3.78 billion, compared to the consensus revenue estimate of $3.57 billion.

What price target have analysts set for CTLT?

8 Wall Street analysts have issued 1-year target prices for Catalent's shares. Their forecasts range from $75.00 to $115.00. On average, they expect Catalent's stock price to reach $105.50 in the next year. This suggests a possible upside of 8.3% from the stock's current price.
View analysts' price targets for Catalent
.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 1,840,000 shares, an increase of 14.3% from the September 30th total of 1,610,000 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 1.3 days.
View Catalent's Short Interest
.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 56, Pay $2.53M)
  • Mr. Alessandro Maselli, Pres & COO (Age 48, Pay $2.09M)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 48, Pay $988.4k)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $1.09M)
  • Ms. Karen A. Flynn, Pres of Biologics & Chief Commercial Officer (Age 57, Pay $665.37k)
  • Mr. Julien Meissonnier, VP & Chief Scientific Officer
  • Mr. Paul Surdez, VP of Investor Relations
  • Mr. Michael J. Grippo, Sr. VP of Strategy & Corp. Devel. (Age 51)
  • Mr. Ricardo Pravda, Sr. VP & Chief HR Officer (Age 49)
  • Dr. Aristippos Gennadios, Pres of Softgel & Oral Technologies (Age 54)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.04%), State Street Corp (3.96%), JPMorgan Chase & Co. (3.22%), Veritas Asset Management LLP (2.84%), Champlain Investment Partners LLC (2.11%) and Earnest Partners LLC (1.54%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Kay A Schmidt, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Peter Zippelius, Ricardo Pravda, Scott Gunther, Steven L Fasman and William Downie.
View institutional ownership trends for Catalent
.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Champlain Investment Partners LLC, JPMorgan Chase & Co., GW&K Investment Management LLC, Principal Financial Group Inc., American International Group Inc., Bernzott Capital Advisors, and Thrivent Financial for Lutherans. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Scott Gunther, and Steven L Fasman.
View insider buying and selling activity for Catalent
.

Which major investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, State Street Corp, Nuveen Asset Management LLC, Great West Life Assurance Co. Can, Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Cubist Systematic Strategies LLC, and Polar Capital LLP. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, and Peter L Buzy.
View insider buying and selling activity for Catalent
.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $97.40.

How big of a company is Catalent?

Catalent has a market capitalization of $16.04 billion and generates $3.09 billion in revenue each year. The company earns $173 million in net income (profit) each year or $1.88 on an earnings per share basis. Catalent employs 13,900 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.